Botulinum toxin A - Merz Pharma

Drug Profile

Botulinum toxin A - Merz Pharma

Alternative Names: Botulinum neurotoxin type A free from complexing proteins (NT 201) - Merz Pharmaceuticals; Incobotulinum toxin A; NT-201; Xeomin

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator BIOTECON Therapeutics
  • Developer Merz Pharma; Merz Pharmaceuticals GmbH; Yale University
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Dystonia; Glabellar lines; Muscle spasticity; Torticollis
  • Phase III Sialorrhoea
  • Phase II Essential tremor
  • No development reported Pain
  • Discontinued Cancer pain

Most Recent Events

  • 01 Jan 2017 Merz Pharmaceuticals completes a phase III extension trial for Muscle spasticity (In children, In adolescents) in Austria, Czech Republic, Estonia, Germany, Israel, Poland, Romania, Russia, Slovakia, South Korea, Turkey and Ukraine (NCT01905683)
  • 01 Dec 2016 Merz Pharmaceuticals completes a phase II trial in Muscle spasticity (spastic equine and equinovarus foot deformation in children with cerebral palsy) in Russia (IM) (NCT02188277)
  • 01 Nov 2016 Merz Pharmaceuticals completes a phase-III clinical trial in Blepharospasm (Treatment-naive) in Greece, Sri Lanka and Malaysia (IM) (NCT01896895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top